Reducing white space in early-stage drug development: Strategies for streamlined success
By Fortrea
How much of the delays and bottlenecks experienced during drug development can be considered ‘white space’, and what can be done during the early stages of the process to reduce such delays and minimise their occurrence later on? In this whitepaper, we discuss common causes of white space in early-stage R&D and explore opportunities to avoid these through better planning and more effective interactions with regulators.